1. Cannabinoids and their effects on pain physiology
Peter Kamerman
Brain Function Research Group, School of Physiology, University of the Witwatersrand
PainSA Congress 2021
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
8. Fisher et al. PAIN 162 (supplement 1): S45-S66, 2021. DOI: 10.1097/j.pain.0000000000001929
Evidence from clinical studies
Effect size
(Hedge’s g standardised mean differences)
Proportion of placebo group with
≥30% pain reduction
Proportion
of
cannabinoid
group
with
≥30%
pain
reduction
Sample size
9. Presidential Task Force on Cannabis and Cannabinoid Analgesia
PAIN 162 (supplement 1): S1-S2, 2021. DOI: 10.1097/j.pain.0000000000002265
10. Soliman et al. PAIN 162 (supplement 1): S26-S44, 2021. DOI: 10.1097/j.pain.0000000000002269
Evidence from animal studies
Effect size
(Hedge’s g standardised mean differences)
Mean = 1.32
11. Presidential Task Force on Cannabis and Cannabinoid Analgesia
PAIN 162 (supplement 1): S1-S2, 2021. DOI: 10.1097/j.pain.0000000000002265
15. Cencioni et al. PLoS 5: e8688, 2010. DOI: 10.1371/journal.pone.0008688
Peripheral: Inhibition of inflammation
INF-gamma
TNF-alpha
16. Weizman et al. Neurology 91: e1285-e1294, 2018. DOI: 10.1212/WNL.0000000000006293
Supraspinal: Reduced brain region connectivity
15 men,
chronic radicular
neuropathic pain
N = 9
N = 6
17. Weizman et al. Neurology 91: e1285-e1294, 2018. DOI: 10.1212/WNL.0000000000006293
Supraspinal: Reduced brain region connectivity
Error bars = standard errors of the mean
18. Weizman et al. Neurology 91: e1285-e1294, 2018. DOI: 10.1212/WNL.0000000000006293
Supraspinal: Reduced brain region connectivity
Connectivity between anterior cingulate cortex and secondary somatosensory cortex
19. Lee et al. PAIN 154: 124–134, 2013. DOI: 10.1016/j.pain.2012.09.017
Supraspinal: Reduced pain unpleasantness
THC Sensitised
Placebo Sensitised
THC No sensitisation
Placebo No sensitisation
Capsaicin
(1% cream)
Control
(placebo cream)
Randomised
order
Agent State
15 healthy men
20. Lee et al. PAIN 154: 124–134, 2013. DOI: 10.1016/j.pain.2012.09.017
Supraspinal: Reduced pain unpleasantness
Error bars = standard errors of the mean
THC
Placebo
21. Lee et al. PAIN 154: 124–134, 2013. DOI: 10.1016/j.pain.2012.09.017
Supraspinal: Reduced pain unpleasantness
Error bars = standard errors of the mean
22. Lee et al. PAIN 154: 124–134, 2013. DOI: 10.1016/j.pain.2012.09.017
Supraspinal: Reduced pain unpleasantness
23. Opioid placebo analgesia
Benedetti et al. Nature Medicine 17:1228-1230, 2011. DOI: 10.1038/nm.2435
Day 1
(torniquet)
No
intervention
No
intervention
Day 2
(torniquet)
Morphine
Morphine
Day 3
(torniquet)
Morphine
Morphine
Day 4
(torniquet)
Placebo
Placebo +
Rimonabant
(CBR inhibitor)
Analgesic response to
morphine
Analgesic response to
placebo
25. Non-opioid placebo analgesia
Benedetti et al. Nature Medicine 17:1228-1230, 2011. DOI: 10.1038/nm.2435
Day 1
(torniquet)
No
intervention
No
intervention
Day 2
(torniquet)
Ketorolac
Ketorolac
Day 3
(torniquet)
Ketorolac
Ketorolac
Day 4
(torniquet)
Placebo
Placebo +
Rimonabant
(CBR inhibitor)
Analgesic response to
ketorolac
Analgesic response to
placebo